New oral pharmaceutical dosage form

Details New oral pharmaceutical dosage form New oral pharmaceutical dosage form

A - Human Necessities

61

K

A61K 31/44 (2006.01) A61K 9/20 (2006.01) A61K 9/22 (2006.01) A61K 9/24 (2006.01) A61K 9/48 (2006.01) A61K 9/52 (2006.01) A61K 31/41 (2006.01) A61K 31/415 (2006.01) A61K 31/4164 (2006.01) A61K 31/43 (2006.01) A61K 31/431 (2006.01) A61K 31/435 (2006.01) A61K 31/4439 (2006.01) A61K 31/545 (2006.01) A61K 31/70 (2006.01) A61K 31/7048 (2006.01) A61K 45/00 (2006.01) A61K 45/06 (2006.01) A61P 1/04 (2006.01) A61P 31/04 (2006.01) C07D 401/12 (2006.01) C07D 403/12 (2006.01) C07D 413/14 (2006.01)

Patent

CA 2186039

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antibacterial compounds in a fixed formulation. The fixed formulation is intended for oral use and in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with Helicobacter infections.

La présente invention concerne une forme galénique pharmaceutique orale comprenant un inhibiteur de la pompe à protons sensible à l'acide et un ou plusieurs composés antibactériens en formulation fixe. Ces formulations fixes, destinées à l'administration orale, se présentent sous forme de comprimé enrobé à film intestinal, de capsule ou d'une forme galénique en comprimé à plusieurs unités. La forme galénique à plusieurs unités est la forme idéale. La nouvelle formulation fixe convient particulièrement au traitement des troubles liés aux infections par Helicobacter.

Affiliated with

Also associated with

Rating

New oral pharmaceutical dosage form does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New oral pharmaceutical dosage form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New oral pharmaceutical dosage form will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2052318